Central Nervous System (CNS) Drug Development Strategy: What is the Role of External Investment in this High-Risk Disease Space?

SUMMARY In 2018, Pfizer announced its plan to stop R&D activity in the central nervous system disease space and to create a venture fund that will invest in biotech firms conducting innovative neuroscience research The strategy of investing in a therapeutic space exclusively via corporate capital is coming into greater…